{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Daly AB"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["203-208"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9873557"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(1)"],"pubmed_abstract":["In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear. In an open-label, single-center, randomized crossover study, 26 adults with type 2 diabetes (7 women and 19 men; (mean ± s.d.) age, 59 ± 11 years; baseline glycated hemoglobin (HbA1c), 75 ± 15 mmol mol<sup>-1</sup> (9.0% ± 1.4%)) underwent two 8-week periods to compare the CamAPS HX fully closed-loop app with standard insulin therapy and a masked glucose sensor (control) in random order, with a 2-week to 4-week washout between periods. The primary endpoint was proportion of time in target glucose range (3.9-10.0 mmol l<sup>-1</sup>). Analysis was by intention to treat. Thirty participants were recruited between 16 December 2020 and 24 November 2021, of whom"],"journal":["Nature medicine"],"pubmed_title":["Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial."],"pmcid":["PMC9873557"],"funding_grant_id":["CL-2020-14-801"],"pubmed_authors":["Daly AB","Hartnell S","Wilinska ME","Evans ML","Nwokolo M","Cezar A","Boughton CK","Hovorka R"],"additional_accession":[]},"is_claimable":false,"name":"Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.","description":"In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear. In an open-label, single-center, randomized crossover study, 26 adults with type 2 diabetes (7 women and 19 men; (mean ± s.d.) age, 59 ± 11 years; baseline glycated hemoglobin (HbA1c), 75 ± 15 mmol mol<sup>-1</sup> (9.0% ± 1.4%)) underwent two 8-week periods to compare the CamAPS HX fully closed-loop app with standard insulin therapy and a masked glucose sensor (control) in random order, with a 2-week to 4-week washout between periods. The primary endpoint was proportion of time in target glucose range (3.9-10.0 mmol l<sup>-1</sup>). Analysis was by intention to treat. Thirty participants were recruited between 16 December 2020 and 24 November 2021, of whom","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-10T06:54:09.807Z","creation":"2025-04-07T03:18:55.131Z"},"accession":"S-EPMC9873557","cross_references":{"pubmed":["36631592"],"doi":["10.1038/s41591-022-02144-z"]}}